Evidence map›Paper›PMID 35253815›Full record

ArticleNanoscale2022

Iron oxide nanoparticles as a drug carrier reduce host immunosuppression for enhanced chemotherapy.

Benqing Zhou, Jinxing Liu, Lu Wang, Meng Wang, Chong Zhao, Haoyu Lin, Yuanke Liang, Rheal A Towner, Wei R Chen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Magnetic nanoparticles as promising materials for the future of medicine.Journal of materials science. Materials in medicine · 2026
    Review
  2. Article
  3. Article
  4. The Fate of Water in Hydrogen-Based Iron Oxide Reduction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Benqing ZhouDepartment of Biomedical Engineering, College of Engineering, Shantou University, Shantou, 515063, China. bqzhou@stu.edu.cn.ORCID http://orcid.org/0000-0003-1131-7591
Jinxing LiuDepartment of Biomedical Engineering, College of Engineering, Shantou University, Shantou, 515063, China. bqzhou@stu.edu.cn.
Lu WangStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, USA.
Meng WangCollege of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen, 518060, China.
Chong ZhaoDepartment of Biomedical Engineering, College of Engineering, Shantou University, Shantou, 515063, China. bqzhou@stu.edu.cn.
Haoyu LinDepartment of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, 515000, China.
Yuanke LiangDepartment of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, 515000, China.
Rheal A TownerAdvanced Magnetic Resonance Center, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, 73104, USA.
Wei R ChenStephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, USA.ORCID http://orcid.org/0000-0002-7133-5794
Shantou University · CNUniversity of Oklahoma · USOklahoma Medical Research Foundation · USShenzhen University · CN

Funding

Mechanistic study on synergistic photo-immunological effects of laser immunotherapy for metastatic cancersR01CA205348 · NCI · UNIVERSITY OF OKLAHOMA · PI CHEN, WEI R. · 2017 to 2021
$1.5M
NCI NIH HHS R01 CA205348
6 · The paper itself

Abstract

Chemotherapy is still regarded as the main modality for cancer treatment. However, it often suppresses the host immune system, resulting in limited therapeutic effects. It is desirable to design a novel chemotherapeutic agent to reduce the level of immunosuppression. Herein, we designed bovine serum albumin (BSA)-bioinspired iron oxide nanoparticles (IONPs) as a nanocarrier to load anticancer drug mitoxantrone (MTX) for enhanced chemotherapy of orthotopic breast cancer. The treatment with IONPs@BSA-MTX complexes increased CD3

Indexed as

Breast NeoplasmsNanoparticlesCell Line, TumorDrug CarriersFemaleHumansImmunosuppression TherapyMagnetic Iron Oxide NanoparticlesSerum Albumin, BovineDrug CarriersSerum Albumin, Bovine

Identifiers

PMID35253815
PMCPMC9001247
OpenAlexW4213198070

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.